Switching antiepileptic drugs could increase risk of seizures

February 17, 2012

The substitution of brand-name antiepileptic drugs with cheaper generic equivalents has been an ongoing point of contention among doctors, federal officials and people with epilepsy.

The U.S. claims generic antiepileptic drugs have the same dosage, purity and strength as their brand-name counterparts and the two are interchangeable. But doctors and people with remain concerned, citing widespread reports of individuals suffering after switching medication.

A new comprehensive review by pharmacists and doctors at the University of Connecticut and Hartford Hospital shows that it is not the anticonvulsant drugs themselves, but the switching aspect that may be causing the problem.

In a review of 89 different studies dating back to 1950, the researchers found that the efficacy, tolerability and safety of brand-name and generic antiepileptic medications are virtually the same. But switching from one form to the other may cause patients to have more hospitalizations and longer hospital stays. The study results were first reported in a Review issued by the Agency for Healthcare Research and Quality (AHRQ) in December 2011.

"If you have epilepsy and want to start on an antiepileptic drug, the evidence is compelling that it doesn't matter if you use a brand- name or a generic product. But if you're already using one version of drug (generic or brand-name), there may be a concern if you switch to something else," says C. Michael White, a pharmacy professor at the University of Connecticut and director of the federally-designated UConn/Hartford Hospital Evidence-Based Practice Center in Hartford, Conn.

The same concerns apply whether a person switches from a brand-name drug to a or from one generic version to another, White says. While many individuals with epilepsy may not experience any problems switching medications, some people may have complications and the consequences could be severe.

White cautions that the studies showing this increased risk of seizures and complications do not use the strongest study designs and the results are far from definitive. But given the high level of concern regarding different versions of antiepileptic drugs, White says it was important to release these latest findings to inform doctors and patients alike.

"It is in cases like this where opinions are the strongest," White says. "Should you act on worrisome but weak evidence knowing that costs for patients and insurers will go up and make it logistically more difficult for the pharmacies or do you wait for higher quality studies to come out before taking action? We wanted to share our findings so people can make informed decisions about their care."

Finding the right medication therapy is vitally important for people with epilepsy. A seizure-free epileptic who suffers a sudden breakthrough seizure can be seriously injured in a fall or car accident and experience other life-changing consequences that may affect their ability to do such things as drive a car or hold a job.

A number of states including Hawaii, Illinois, Tennessee and Utah, have passed legislation in recent years preventing the substitution of generic antiepileptic drugs for brand-name products without a patient's consent. Connecticut passed its Patient Prescription Protection Act last year. More than 20 other states have considered passing a law.

"Informed consent is the critical issue here," says Alexandra Finucane, executive vice-president of the national Epilepsy Foundation. "Many people are able to go from one formulation of an epilepsy drug to another, brand to generic, generic to generic. Some however, are at risk for having a breakthrough seizure when switching among different manufacturers' formulations.

"The patient and his or her doctor needs to know and consent in advance when a switch is being considered, as there may be a history of problems with switching and a need for monitoring during the change," Finucane continues. "In some cases, the treating doctor will recommend that the patient stays on the same formulation by the same company. For some people with epilepsy, switching could be a matter of life and death."

Generic equivalents of popular such as carbamazepine, phenobarbital, phenytoin and valproic acid have existed for more than a decade. With generic drugs costing anywhere from a few cents to five dollars less per tablet than brand-name medication, they have become a popular option for patients, health insurers, and pharmacies looking to save money.

Unless a patient is specifically prescribed a brand-name medication only, pharmacists can substitute a generic equivalent without informing the patient or their physician. Patients also may have little or no ability to maintain one specific generic medication at the pharmacy they visit as pharmacies frequently change their generic brands based on market supplies, costs and other factors.

The American Academy of Neurology has issued two position papers stating that it has concerns with generic antiepileptic medication and that physicians should approve all generic substitutions. The American Epilepsy Society (AES) and the French Chapter of the International League Against Epilepsy have also expressed concerns while the Italian League Against Epilepsy has concluded that while generic medications offer a valuable, low-cost alternative in epilepsy management, generic substitution is not recommended in patients who have achieved remission using a brand-name product.

White says more randomized controlled trials are needed to clarify why switching medication is a problem for some people. The FDA is currently funding three studies that will further explore the efficacy and safety of brand-name and generic antiepileptic medication. The Epilepsy Foundation of America and the AES are also supporting studies regarding the issue.

The clinical trial data reviewed in the UConn/Hartford Hospital study was limited by the small size of the trials reviewed, the short duration of follow-up study and a lack of clarity as to what specific generic products were used. FDA rules require generic drugs to have the same exact amount of active medication as their brand-name equivalent, and that the rate of absorption (e.g., immediate release, delayed release, extended release) be identical. To be equivalent by FDA standards, the amount of drug absorbed must be statistically similar between a generic product and the brand product.

Explore further: Variation in make-up of generic epilepsy drugs can lead to dosing problems

Related Stories

Variation in make-up of generic epilepsy drugs can lead to dosing problems

June 30, 2011
Generic anti-epilepsy drugs, pharmaceutical products similar to brand-name versions, save consumers billions of dollars each year, but some are different enough from branded formulations that they may not be effective, particularly ...

No difference in brand name and generic drugs regarding thyroid dysfunction

July 11, 2011
There is no difference between brand-name and generic drug formulations of amiodarone -- taken to control arrhythmia – in the incidence of thyroid dysfunction, according to a study in CMAJ (Canadian Medical Association ...

Substitution of brand name with generic drug proves safe for transplant recipients

September 13, 2011
A new study published in the American Journal of Transplantation reveals that substitution of a brand name immunosuppressive drug with a generic (manufactured by Sandoz) for preventing rejection of transplanted organs appears ...

Americans turn to generic medications in 2010: report

April 22, 2011
(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Recommended for you

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.